↓ Skip to main content

Response‐adapted treatment with rituximab, bendamustine, mitoxantrone, and dexamethasone followed by rituximab maintenance in patients with relapsed or refractory follicular lymphoma after first‐line…

Overview of attention for article published in Cancer Medicine, October 2019
Altmetric Badge

About this Attention Score

  • Good Attention Score compared to outputs of the same age (66th percentile)
  • High Attention Score compared to outputs of the same age and source (85th percentile)

Mentioned by

twitter
9 tweeters
facebook
1 Facebook page

Readers on

mendeley
3 Mendeley
You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output. Click here to find out more.
Title
Response‐adapted treatment with rituximab, bendamustine, mitoxantrone, and dexamethasone followed by rituximab maintenance in patients with relapsed or refractory follicular lymphoma after first‐line immunochemotherapy: Results of the RBMDGELTAMO08 phase II trial
Published in
Cancer Medicine, October 2019
DOI 10.1002/cam4.2555
Pubmed ID
Authors

Francisco‐Javier Peñalver, José‐Antonio Márquez, Soledad Durán, Pilar Giraldo, Alejandro Martín, Carlos Montalbán, Juan‐Manuel Sancho, María‐José Ramírez, María‐José Terol, Francisco‐Javier Capote, Antonio Gutiérrez, Blanca Sánchez, Andrés López, Antonio Salar, Gil Rodríguez‐Caravaca, Miguel Canales, María‐Dolores Caballero

Twitter Demographics

The data shown below were collected from the profiles of 9 tweeters who shared this research output. Click here to find out more about how the information was compiled.

Mendeley readers

The data shown below were compiled from readership statistics for 3 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
Unknown 3 100%

Demographic breakdown

Readers by professional status Count As %
Researcher 1 33%
Student > Postgraduate 1 33%
Unknown 1 33%
Readers by discipline Count As %
Pharmacology, Toxicology and Pharmaceutical Science 1 33%
Biochemistry, Genetics and Molecular Biology 1 33%
Unknown 1 33%

Attention Score in Context

This research output has an Altmetric Attention Score of 5. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 03 December 2019.
All research outputs
#3,586,665
of 14,083,883 outputs
Outputs from Cancer Medicine
#245
of 1,358 outputs
Outputs of similar age
#86,413
of 262,632 outputs
Outputs of similar age from Cancer Medicine
#13
of 90 outputs
Altmetric has tracked 14,083,883 research outputs across all sources so far. This one has received more attention than most of these and is in the 74th percentile.
So far Altmetric has tracked 1,358 research outputs from this source. They typically receive a little more attention than average, with a mean Attention Score of 5.4. This one has done well, scoring higher than 81% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 262,632 tracked outputs that were published within six weeks on either side of this one in any source. This one has gotten more attention than average, scoring higher than 66% of its contemporaries.
We're also able to compare this research output to 90 others from the same source and published within six weeks on either side of this one. This one has done well, scoring higher than 85% of its contemporaries.